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This study demonstrates that the Epstein-Barr virus protein LMP1 activates a specific subset of NF-kB/Rel
proteins in the C33 epithelial cell line. Western immunoblot analysis used to analyze the intracellular
distribution and abundance of the proteins present in these complexes demonstrated that levels of the p50 and
p52 proteins were significantly elevated in the nuclei of LMP1-expressing cells. The data also suggest that
LMP1 facilitates the translocation of p50 to the nucleus and may affect the processing of the p100 and p105
precursor proteins or the stability of p52 and p50.
Epstein-Barr virus (EBV), a herpesvirus which infects both
B lymphocytes and epithelial cells in vivo, causes infectious
mononucleosis and posttransplant lymphoma and is associated
with both Burkitt’s lymphoma and nasopharyngeal carcinoma
(NPC). EBV is consistently detected in all examples of NPC
regardless of geographic location or ethnic background of the
patient (23). Molecular analysis of the genomic structure of
EBV found in NPC tumor cells revealed that NPC is a clonal
proliferation of a single EBV-infected cell, indicating that
EBV infection is an early occurrence in the development of
NPC (24, 25).
Latent membrane protein 1 (LMP1) is a viral protein tran-
scribed in most NPCs and is detected at the protein level in 35
to 65% of all NPCs (6, 9, 32). LMP1 is necessary for the
transformation of B lymphocytes and transforms rodent fibro-
blasts (2, 16, 29). LMP1 also affects epithelial cells. LMP1
transgenic mice have altered keratin expression and exhibit
hyperplasia of the skin (31). In addition, nontumorigenic epi-
thelial cell lines expressing LMP1 are inhibited in their ability
to respond to terminal differentiation signals (8, 33).
Recent work with fibroblasts, B lymphocytes, and T lympho-
cytic cell lines has demonstrated that LMP1 activates NF-kB/
Rel proteins (11, 17). Distinct NF-kB/Rel family complexes,
consisting of heterodimeric and homodimeric combinations of
the various NF-kB/Rel family proteins—p65 (RelA), RelB,
c-Rel, p50 (NFkB1), and p52 (NFkB2)—can be activated in
different cell types in response to similar stimuli (18, 20). In
addition, different NF-kB family proteins have varied affects
on different NF-kB-responsive promoters (10, 19). Therefore,
identification of the specific complexes induced by LMP1 in
epithelial cells may be an important step in determining a
mechanism by which LMP1 alters cellular gene expression and
growth regulation in these cells.
To determine whether LMP1 activated NF-kB in epithelial
cells, epithelial cell lines stably expressing LMP1 were estab-
lished by using C33 cells, a human papillomavirus-negative
cervical carcinoma cell line (1). LMP1 in these cells was ex-
pressed from KLMPneo, a pGem-based vector containing a
neomycin resistance gene and LMP1 coding sequences under
the control of a keratin 14 promoter (14, 29). Negative control
stable clones contained only the neomycin resistance gene in
the same vector. The growth rates of the LMP1-expressing and
-nonexpressing cells were similar under standard culture con-
ditions; however, in the absence of fetal calf serum LMP1-
expressing cells survived longer (reference 21 and data not
shown).
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FIG. 1. (A) LMP1 activation of NF-kB/Rel in epithelial cells. EMSA were
performed by using a probe containing the NF-kB site in the H-2Kb major
histocompatibility complex class I gene. Portions (4 mg) of protein from cyto-
plasmic extracts from LMP1-expressing (LMP-1 cyt) and control (Neo cyt) cells
and from nuclear extracts from LMP1-expressing (LMP-1 nuc) and control (Neo
nuc) cells were used in each assay. A 10-fold excess of cold probe was added to
show specific competition (LMP-1 nuc 1 comp). (B) Transcriptional activity of
NF-kB/Rel family proteins activated by LMP1 in epithelial cells. A plasmid
containing a CAT reporter gene expressed from a minimal fos promoter with
three intact NF-kB sites upstream (MHC-NFkB CAT) was cotransfected into
C33 cells with either an LMP1-expressing plasmid (LMP-1) or a control plasmid
(GPT). The LMP1-expressing plasmid and the control were also cotransfected
with a similar reporter construct containing mutant NF-kB sites (MHCmut-
NF-kB CAT).
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To detect activated NFkB/Rel proteins in extracts from
LMP1-expressing and -nonexpressing clones, electrophoretic
mobility shift assays (EMSA) were performed as previously
described by using a labelled oligonucleotide probe containing
an NF-kB site that is recognized by most NF-kB/Rel com-
plexes (3, 26). In EMSA performed with nuclear extracts from
the LMP1-expressing C33 cell lines, two shifted bands were
present (Fig. 1A; compare lane 2 and lane 1). Further analysis
revealed that the upper band could be resolved into two shifted
bands (Fig. 2A). These shifted bands could be eliminated by
the addition of excess cold probe (Fig. 1A, lane 3). Similar
results were obtained with two LMP1-expressing clones de-
rived from BALB/MK cells, a mouse keratinocyte cell line (30)
(data not shown).
EMSA were also performed with cytoplasmic extracts and
revealed a predominant shifted band in extracts from both
LMP-expressing and non-LMP-expressing cells. This band was
significantly greater in the lane showing results for the assay
performed with extracts from LMP1-expressing cells (Fig. 1A,
lanes 4 and 5).
These EMSA results demonstrated an increase in the
amount of protein complexes available for binding to the
NF-kB probe in the cytoplasm and the new appearance of
complexes in the nuclei of LMP1-expressing cells.
That the protein binding demonstrated by the shifts seen in
the experiments described above had a functional effect on
promoters containing an NF-kB site was verified by the fact
that a chloramphenicol acetyltransferase (CAT) reporter gene
(MHC-NF-kB CAT) expressed from an NFkB-responsive pro-
moter was transactivated in cells transiently expressing LMP1
(3, 29). LMP1 increased CAT expression approximately 30-
fold over the levels seen in non-LMP1-expressing cells. The
specificity of this transactivation was demonstrated by the ob-
servation that a reporter plasmid containing point mutations in
the NF-kB sites was transactivated at only trace levels (Fig.
1B).
To demonstrate that the proteins binding to the probe were
NF-kB/Rel proteins, and to identify the specific NF-kB/Rel
proteins that are activated by LMP1, antibodies to p50 (NFkB-
1), p52 (NFkB-2), and p65 (RelA) were preincubated with
nuclear extracts prior to addition of the probe. These super-
shift assays demonstrated that the lower complex (L) was su-
pershifted only by the p50 antibody (Fig. 2A, lane 2). The
upper complex (U) was supershifted by both p52 and p65
antibodies (Fig. 2A, lanes 7 and 10). Although it is less clear,
the middle complex (M) was diminished by both p50 and p52
antibodies (Fig. 2A, lanes 2 and 10). c-Rel and RelB antibodies
were unable to shift any of the complexes present in the nu-
clear extracts (data not shown).
Complex L comigrates with the band known to represent the
p50/p50 homodimer in extracts from HeLa cells activated with
tumor necrosis factor alpha (TNF-a). Cross-linking experi-
ments with a bromodeoxyuridine-labelled probe also indicated
that this complex is a p50/p50 homodimer (4) (data not
shown).
These data demonstrated that complex U contains p65 and
p52 and that complex L contains p50 and suggest that complex
M contains p50 and p52.
FIG. 2. Identification of the NF-kB/Rel components of LMP1-activated complexes. (A) Supershift assays were performed with nuclear extracts from LMP1-
expressing cells by using antibodies to p52, p50, and p65 (Santa Cruz). Where indicated (1), extracts were preincubated for 5 min with the indicated antibody or
antibody plus specific or nonspecific peptide (pep), prior to addition of the probe. U, M, and L refer to the upper, middle, and lower complexes as described in the
text. p50s, p52s, and p65s refer to the shifted bands resulting from addition of p50, p52, and p65 antibody. (B) Supershift assays were performed with cytoplasmic extracts
from LMP1-expressing cells preincubated with deoxycholate. Cytoplasmic extracts were preincubated with p52, p50, or p65 antibody, or antibody plus the designated
specific or nonspecific peptide, 5 min prior to the addition of the labelled probe. Portions (4 mg) of protein from cytoplasmic extracts (cyt) from LMP1-expressing
(LMP-1) and control cells (Neo) were used in each assay.
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To identify the NF-kB proteins present in the cytoplasm,
supershifts were performed with the cytoplasmic extracts from
both LMP1-expressing and non-LMP1-expressing cells. Re-
sults from supershifts done with LMP1-expressing cells were
identical to those obtained with extracts from non-LMP1-ex-
pressing cells. The results from assays done with the LMP1-
expressing cells are shown. The predominant complex found in
the cytoplasmic extracts was supershifted by both p65 and p50
antibodies, but not by a p52 antibody (Fig. 2B, lanes 6, 3, and
9). A very faint supershift was obtained with antibodies to
c-Rel and RelB (data not shown). These results indicated that
the predominant cytoplasmic complex contains p65 and p50.
In summary, these experiments suggest that the nuclear NF-
kB/Rel complexes activated by LMP1 include a p52/p65 dimer,
a p50/p50 homodimer, and a possible p50/p52 heterodimer.
The predominant complex in the cytoplasm of both LMP1-
expressing and non-LMP1-expressing cells is most likely a p50/
p65 dimer. These data indicate that the p50/p65 complexes are
retained in the cytoplasm even as other complexes are acti-
vated by LMP1.
Western immunoblot analysis was performed to determine
the effects of LMP1 on the abundance and intracellular loca-
tion of the components of the specific complexes. Analysis of
whole-cell extracts from LMP1-expressing and non-LMP1-ex-
pressing cells was performed by using antibodies to p50, p52,
and p65. Equal amounts of protein were loaded into each lane
as determined by a Bradford assay. While the levels of p105
and p100 precursor proteins were variable, levels of p50 and
p52 were consistently elevated in all three LMP1-expressing
clones (LMP1 1B4, LMP1 1C1, and LMP1 2C) compared with
the levels found in two control clones (Neo 1C and Neo 1b)
(Fig. 3A and B). The average increases in the levels of p50 and
p52 in LMP1-expressing cells over several experiments were
4.4- and 5.1-fold, respectively. Median increases were 3.4- and
4.3-fold, respectively. Similar analysis of p65, RelB, and c-Rel
levels in whole-cell extracts detected no consistent differences
in the levels of these proteins in the LMP1-expressing clones
versus the nonexpressing clones (Fig. 3C and data not shown).
Western blot analysis of the nuclear and cytoplasmic extracts
demonstrated that while p50 was present in the cytoplasm of
both LMP1-expressing and non-LMP1-expressing cells, it was
present in the nuclei of only LMP1-expressing cells. In con-
trast, while p52 was present in both the nuclei and the cyto-
plasm of LMP1-expressing and non-LMP1-expressing cells, it
was considerably more abundant in both the nuclei and the
cytoplasm of LMP1-expressing cells. This suggests that LMP1
interferes with some mechanism that retains p50, but not p52,
in the cytoplasm (Fig. 4). No consistent difference in the in-
tracellular distribution of p65 in LMP1-expressing versus non-
LMP1-expressing cells was found (data not shown).
Mutated or abnormally regulated NF-kB/Rel proteins have
been shown to contribute to oncogenesis (15). LMP1 may
regulate NF-kB/Rel proteins through cleavage of the p105 and
p100 precursors. The three complexes activated by LMP1 all
contain p50 or p52, whose total levels are increased by LMP1.
The increase in the total amount of p50 and p52 seen here
suggests that LMP1 affects the processing of the precursor
proteins or increases the synthesis or stability of the processed
or unprocessed forms. The degradation and resynthesis of IkB,
a process which has been found to be involved in NF-kB/Rel
activation, and which has recently been shown to play a role in
the LMP1 activation of NF-kB/Rel in B-lymphocytic cell lines,
could also contribute to NF-kB/Rel activation in these cells (5,
7, 12, 13, 27, 28).
This study reveals that a specific subset of NF-kB/Rel com-
plexes are activated by LMP1, including p52/p65, p50/p50, and
p50/p52. These forms of NF-kB/Rel activated by LMP1 are
different from the p52/p65, p65/p50, and p50/p50 complexes
believed to be activated in LMP1-expressing B-lymphocytic
cell lines (13). In epithelial cells, through the action of these
different complexes, NF-kB could specifically affect cellular
gene expression in a way that is distinct from that seen in B
lymphocytes. Complexes containing p52/p65 and p50/p52 have
been identified as a subset of the complexes activated by
TNF-a in HeLa cells, another epithelial cell line. Recent work
by Mosialos et al. has demonstrated that LMP1 interacts with
FIG. 3. Expression of p50, p52, and p65. Western blots showing the levels of
p50 (A), p52 (B), and p65 (C) proteins in LMP1-expressing (LMP-1 1B4, LMP-1
1C1, and LMP-1 2C) and neomycin control (Neo 1C and Neo 1b) clones. Rabbit
antisera to the amino termini of p50 (1:1,000) and of p52 (1:1,000) or rabbit
antisera to p65 (1:200) were used as the primary antibodies. As indicated, a
control lane was incubated with primary antibody in the presence of 1 mg of
competing peptide. A 40-mg portion of protein was loaded into each lane.
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two signalling proteins which interact with members of the
TNF-a receptor family (22). Through these proteins, LMP1
may activate a subset of the NF-kB complexes activated by
TNF-a.
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